SNC
TEVA icon

Stifel Nicolaus & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Stifel Nicolaus & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$30.3M Buy
802,900
+12,035
+2% +$469K 0.5% 38
2013
Q2 		$31M Buy
+790,865
New +$30.8M 0.56% 37

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Stifel Nicolaus & Co's TEVA Position: Q3 2013 in Review

Stifel Nicolaus & Co increased its Teva Pharmaceuticals (TEVA) stake by 1.5% in Q3 2013, buying an estimated $469K and bringing the position to 802,900 shares worth $30.3M. The position accounts for 0.5% of the portfolio, ranked #38.

Stifel Nicolaus & Co first reported a position in TEVA in Q2 2013 and has held it in 2 quarters since. The position peaked at $31M in Q2 2013. 705 funds tracked by Wall St. Rank hold TEVA as of Q3 2013.

  • Stifel Nicolaus & Co held 802,900 shares of Teva Pharmaceuticals worth $30.3M as of Q3 2013.
  • Stifel Nicolaus & Co bought 12,035 Teva Pharmaceuticals shares in Q3 2013, an estimated $469K.
  • Teva Pharmaceuticals made up 0.5% of Stifel Nicolaus & Co's portfolio in Q3 2013, its #38 holding.
  • Stifel Nicolaus & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 2 quarters since.
  • Stifel Nicolaus & Co's Teva Pharmaceuticals position peaked at $31M in Q2 2013.
  • 705 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2013.

Based on Stifel Nicolaus & Co's 13F filing for Q3 2013, filed 13 Nov 2013.